HL7 FHIR® Implementation Guide: Breast Cancer Data, Release 1 - US Realm (Draft for Comment)

This page is part of the Breast Cancer Data Logical Models and FHIR Profiles (v0.1.0: STU 1 Draft) based on FHIR (HL7® FHIR® Standard) R3. No current official version has been published yet. For a full list of available versions, see the Directory of published versions

OncotypeDxDCISRiskScoreInterpretationVS

{
  "resourceType" : "ValueSet",
  "id" : "oncology-OncotypeDxDCISRiskScoreInterpretationVS",
  "text" : {
    "status" : "generated",
    "div" : "<div xmlns="http://www.w3.org/1999/xhtml">
<p><b>BC OncotypeDxDCISRiskScoreInterpretationVS ValueSet</b></p>
<p>Intepretation of OncotypeDX DCIS (Ductal Carcinoma In Situ) Recurrence Score</p>
</div>"
  },
  "url" : "http://hl7.org/fhir/us/breastcancer/ValueSet/oncology-OncotypeDxDCISRiskScoreInterpretationVS",
  "identifier" : [
    {
      "system" : "http://hl7.org/fhir/us/breastcancer",
      "value" : "oncology.OncotypeDxDCISRiskScoreInterpretationVS"
    }
  ],
  "version" : "0.1.0",
  "name" : "OncotypeDxDCISRiskScoreInterpretationVS",
  "title" : "BC OncotypeDxDCISRiskScoreInterpretationVS ValueSet",
  "status" : "draft",
  "date" : "2018-04-01T00:00:00+11:00",
  "publisher" : "The HL7 Cancer Interoperability Group sponsored by Clinical Interoperability Council Work Group (CIC)",
  "contact" : [
    {
      "telecom" : [
        {
          "system" : "url",
          "value" : "http://standardhealthrecord.org"
        }
      ]
    }
  ],
  "description" : "Intepretation of OncotypeDX DCIS (Ductal Carcinoma In Situ) Recurrence Score",
  "compose" : {
    "include" : [
      {
        "system" : "http://hl7.org/fhir/us/breastcancer/CodeSystem/oncology-OncotypeDxDCISRiskScoreInterpretationCS",
        "concept" : [
          {
            "code" : "low_risk",
            "display" : "Recurrence Score lower than 38: The cancer has a low risk of recurrence. The benefit of chemotherapy is likely to be small and will not outweigh the risks of side effects."
          },
          {
            "code" : "intermediate_risk",
            "display" : "Recurrence Score of 39 up to and including 54: The cancer has an intermediate risk of recurrence. It’s unclear whether the benefits of chemotherapy outweigh the risks of side effects."
          },
          {
            "code" : "high_risk",
            "display" : "Recurrence Score greater than or equal to 55: The cancer has a high risk of recurrence, and the benefits of chemotherapy are likely to be greater than the risks of side effects."
          }
        ]
      }
    ]
  }
}